Early Development
The Belgian Association of Phase I Units (BAPU) was formed as a result of the EU Clinical Trials Directive of 2004 where a need was identified to create an umbrella organization for centers dedicated to Phase I clinical research. BAPU was born on 14 January 2005. 5 Academic Research Organisations, 2 Clinical Research Organisations and 2 company-owned organisations were the first members, and still are the current members.
The principal responsibilities include supporting its organisations in their work, representing their interests at regulators, provide a source of continued education through an internal education cycle as well as symposia.
Over time BAPU has extended its reach to close collaboration with sister organisations in Germany, France and the UK. BAPU is also a member of Eufemed (= European Federation for Exploratory Medicines Development).
We can rely on our Healixia Early Development Education Group for the elaboration of our trainings/events/sessions on the topics with a link to Early Development. You can find the members here:
|
|
|
|
|
|
|
|
|
|
Sylvie Rottey
Professor, Medical Oncologist & Clinical Pharmacologist, Head of Drug Research Unit Ghent and Head of Departement Medical Oncology at UGent
Jan de Hoon
Professor in Pharmacology and Head of Department of the Center for Clinical Pharmacology at UZ Leuven
Annick van Riel
SGS Belgium nv
Josue MFOPOU KUNJOM
Pfizer Clinical Research Unit
Benjamin Boinem
Academic Hospital of Liège (Sart-Tilman)
Erik Mannaert
Janssen Pharmaceutica NV
Fien De Boever
UZ Gent - CEVAC
Ilse De Coster
VAXINFECTIO/CEV ANTWERP
Isabel Leroux
UZ Gent - CEVAC
Leen Suykens
VAXINFECTIO/CEV ANTWERP
Jelle Klein
SGS Belgium nv
-
15 January '25Human Pharmacology course: Pharmacokinetics, pharmacodynamics and biomarkers in early clinical development
Leuven and GentRead moreRegistration possible until December 18, 2024
Healixia/EUFEMED Certificate Course in Human Pharmacology - Module 4
This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. The training provides an overview on pharmacokinetics (PK), pharmacodynamics (PD) and biomarkers in early clinical drug development spanning from non-clinical pharmacology over first-in-man studies to proof-of-concept clinical trials.